BioTuesdays

Tag - GMTX

Gemini Therapeutics
Markets

SVB Leerink cuts Gemini Therapeutics to MP; PT to $2

SVB Leerink downgraded Gemini Therapeutics (NASDAQ:GMTX) to “market perform” from “outperform” and slashed its price target to $2 from $10, citing an unexpected leadership transition and corporate restructuring. The...

March 3, 2022
Gemini Therapeutics
Markets

HCW starts Gemini Therapeutics at buy; PT $20

H.C. Wainwright launched coverage of Gemini Therapeutics (NASDAQ:GMTX) with a “buy” rating and $20 price target. The stock closed at $2.43 on Dec. 14. Gemini is developing precision medicines for the treatment of...

December 15, 2021